[
  {
    "ts": "2026-01-14T07:37:10+00:00",
    "headline": "Lilly, Novo test direct-to-employer approach that could cut out PBMs and lower costs",
    "summary": "The GLP-1 giants are the first to try out this new model, but more companies may follow.",
    "url": "https://www.pharmavoice.com/news/lilly-novo-direct-employer-drug-cost-pbm-consumer/809575/",
    "source": "Pharma Voice",
    "provider": "yfinance",
    "raw": {
      "id": "4db4d2bb-ad4e-395e-b77e-aa626692ff12",
      "content": {
        "id": "4db4d2bb-ad4e-395e-b77e-aa626692ff12",
        "contentType": "STORY",
        "title": "Lilly, Novo test direct-to-employer approach that could cut out PBMs and lower costs",
        "description": "",
        "summary": "The GLP-1 giants are the first to try out this new model, but more companies may follow.",
        "pubDate": "2026-01-14T07:37:10Z",
        "displayTime": "2026-01-14T07:37:10Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharma_voice_330/3b2c31d041e3be1658c67634d44630da",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "Health insurer Molina Healthcare reported second-quarter results on July 27, 2022.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hnFyQHoVgPhLIfqyHtZ7mA--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharma_voice_330/3b2c31d041e3be1658c67634d44630da.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/U28tfaLGLsJT_IbxwN3OmQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharma_voice_330/3b2c31d041e3be1658c67634d44630da.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharma Voice",
          "url": "https://www.pharmavoice.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmavoice.com/news/lilly-novo-direct-employer-drug-cost-pbm-consumer/809575/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lilly-novo-test-direct-employer-073710828.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-14T13:00:20+00:00",
    "headline": "Nvidia Eyes First Breakout Of 2026. These Clues — And An Innovative Deal With Eli Lilly — Bode Well.",
    "summary": "Now set to collaborate with Eli Lilly to develop drugs in the AI era, Nvidia looks to trigger a new climb.",
    "url": "https://www.investors.com/research/breakout-stocks-technical-analysis/nvidia-stock-eyes-first-breakout-of-2026-with-eli-lilly-ai-collaboration/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "29d673eb-8756-34b8-b3de-fb7f5eab5629",
      "content": {
        "id": "29d673eb-8756-34b8-b3de-fb7f5eab5629",
        "contentType": "STORY",
        "title": "Nvidia Eyes First Breakout Of 2026. These Clues — And An Innovative Deal With Eli Lilly — Bode Well.",
        "description": "",
        "summary": "Now set to collaborate with Eli Lilly to develop drugs in the AI era, Nvidia looks to trigger a new climb.",
        "pubDate": "2026-01-14T13:00:20Z",
        "displayTime": "2026-01-14T13:00:20Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/29d673eb-8756-34b8-b3de-fb7f5eab5629/nvidia-eyes-first-breakout-of.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/f5161cefefbf4b4e513a9ed2c34cd885",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3Qspy2SfrKIYEshxHRa3_A--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/f5161cefefbf4b4e513a9ed2c34cd885.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/duRT6Dnmz77p83MsqEDWsg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/f5161cefefbf4b4e513a9ed2c34cd885.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/research/breakout-stocks-technical-analysis/nvidia-stock-eyes-first-breakout-of-2026-with-eli-lilly-ai-collaboration/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-14T14:00:00+00:00",
    "headline": "Ontario Pioneers Access to Treatment for Severe Alopecia Areata with Lilly's Olumiant®",
    "summary": "Eli Lilly Canada Inc. (\"Lilly\") announced today that Ontario leads the way as the first province to add Olumiant® for severe alopecia areata to its public drug formulary—the first and only treatment for adult patients with severe alopecia areata available through public coverage.",
    "url": "https://finance.yahoo.com/news/ontario-pioneers-access-treatment-severe-140000180.html",
    "source": "CNW Group",
    "provider": "yfinance",
    "raw": {
      "id": "1e955332-af2e-379c-acce-1aa99ebb1f22",
      "content": {
        "id": "1e955332-af2e-379c-acce-1aa99ebb1f22",
        "contentType": "STORY",
        "title": "Ontario Pioneers Access to Treatment for Severe Alopecia Areata with Lilly's Olumiant®",
        "description": "",
        "summary": "Eli Lilly Canada Inc. (\"Lilly\") announced today that Ontario leads the way as the first province to add Olumiant® for severe alopecia areata to its public drug formulary—the first and only treatment for adult patients with severe alopecia areata available through public coverage.",
        "pubDate": "2026-01-14T14:00:00Z",
        "displayTime": "2026-01-14T14:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/cnwgroup.com/947b60ce205f1931a0aa62c5e816eb95",
          "originalWidth": 375,
          "originalHeight": 204,
          "caption": "Lilly Canada (CNW Group/Eli Lilly Canada Inc.)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ZmcJfFgf4UXt.L40lreuUw--~B/aD0yMDQ7dz0zNzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/cnwgroup.com/947b60ce205f1931a0aa62c5e816eb95.cf.webp",
              "width": 375,
              "height": 204,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g2WN07FmhnEZMQ9R5QRFHw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/cnwgroup.com/947b60ce205f1931a0aa62c5e816eb95.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "CNW Group",
          "url": "http://www.newswire.ca/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/ontario-pioneers-access-treatment-severe-140000180.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ontario-pioneers-access-treatment-severe-140000180.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-14T13:52:00+00:00",
    "headline": "Is It Time to Dump Your Shares of Eli Lilly?",
    "summary": "What happens with Eli Lilly's GLP-1 shot now that Novo Nordisk has come out with a GLP-1 pill?",
    "url": "https://www.fool.com/investing/2026/01/14/is-it-time-to-dump-your-shares-of-eli-lilly/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "235751e7-3a81-300e-a75e-62bf22860961",
      "content": {
        "id": "235751e7-3a81-300e-a75e-62bf22860961",
        "contentType": "STORY",
        "title": "Is It Time to Dump Your Shares of Eli Lilly?",
        "description": "",
        "summary": "What happens with Eli Lilly's GLP-1 shot now that Novo Nordisk has come out with a GLP-1 pill?",
        "pubDate": "2026-01-14T13:52:00Z",
        "displayTime": "2026-01-14T13:52:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/80506abbdcafdf6360e2a55d5ea572b9",
          "originalWidth": 1200,
          "originalHeight": 800,
          "caption": "People in business attire leaving the starting line on a track.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lm9DmQt02EysCsC2mpKtkA--~B/aD04MDA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/80506abbdcafdf6360e2a55d5ea572b9.cf.webp",
              "width": 1200,
              "height": 800,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IOIKHIROappQImz9pswWvQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/80506abbdcafdf6360e2a55d5ea572b9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/01/14/is-it-time-to-dump-your-shares-of-eli-lilly/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/time-dump-shares-eli-lilly-135200635.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-14T12:45:00+00:00",
    "headline": "PFE Market Cap Falls More Than $7B in a Month: How to Play the Stock",
    "summary": "Pfizer shares fall nearly 5% in a month after weak 2026 guidance, sparking debate over buying the dip or staying cautious.",
    "url": "https://finance.yahoo.com/news/pfe-market-cap-falls-more-124500360.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "db723028-55a5-3fcf-9b54-44d62c81b401",
      "content": {
        "id": "db723028-55a5-3fcf-9b54-44d62c81b401",
        "contentType": "STORY",
        "title": "PFE Market Cap Falls More Than $7B in a Month: How to Play the Stock",
        "description": "",
        "summary": "Pfizer shares fall nearly 5% in a month after weak 2026 guidance, sparking debate over buying the dip or staying cautious.",
        "pubDate": "2026-01-14T12:45:00Z",
        "displayTime": "2026-01-14T12:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/A9LQHlDmqgPJbKsotfjd8w--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o5.ym16dSp_UIlCHMRMZUw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfe-market-cap-falls-more-124500360.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfe-market-cap-falls-more-124500360.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-14T15:49:26+00:00",
    "headline": "Nvidia Eyes First Breakout Of 2026 — But Resistance Remains",
    "summary": "Now set to collaborate with Eli Lilly to develop drugs in the AI era, Nvidia looks to trigger a new climb.",
    "url": "https://www.investors.com/research/breakout-stocks-technical-analysis/nvidia-stock-eyes-first-breakout-of-2026-with-eli-lilly-ai-collaboration/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "29d673eb-8756-34b8-b3de-fb7f5eab5629",
      "content": {
        "id": "29d673eb-8756-34b8-b3de-fb7f5eab5629",
        "contentType": "STORY",
        "title": "Nvidia Eyes First Breakout Of 2026 — But Resistance Remains",
        "description": "",
        "summary": "Now set to collaborate with Eli Lilly to develop drugs in the AI era, Nvidia looks to trigger a new climb.",
        "pubDate": "2026-01-14T15:49:26Z",
        "displayTime": "2026-01-14T15:49:26Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/29d673eb-8756-34b8-b3de-fb7f5eab5629/nvidia-eyes-first-breakout-of.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/f5161cefefbf4b4e513a9ed2c34cd885",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3Qspy2SfrKIYEshxHRa3_A--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/f5161cefefbf4b4e513a9ed2c34cd885.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/duRT6Dnmz77p83MsqEDWsg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/f5161cefefbf4b4e513a9ed2c34cd885.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/research/breakout-stocks-technical-analysis/nvidia-stock-eyes-first-breakout-of-2026-with-eli-lilly-ai-collaboration/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "^IXIC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-14T14:50:04+00:00",
    "headline": "Here's Why Eli Lilly (LLY) is a Strong Momentum Stock",
    "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
    "url": "https://finance.yahoo.com/news/heres-why-eli-lilly-lly-145004555.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "99f2e8da-80d9-3697-9065-bc516c613fe0",
      "content": {
        "id": "99f2e8da-80d9-3697-9065-bc516c613fe0",
        "contentType": "STORY",
        "title": "Here's Why Eli Lilly (LLY) is a Strong Momentum Stock",
        "description": "",
        "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
        "pubDate": "2026-01-14T14:50:04Z",
        "displayTime": "2026-01-14T14:50:04Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/d2f7ed3d1940141716bfd200f5c94c6b",
          "originalWidth": 900,
          "originalHeight": 711,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Bjs59nqcRE8iEsudL3mMxA--~B/aD03MTE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d2f7ed3d1940141716bfd200f5c94c6b.cf.webp",
              "width": 900,
              "height": 711,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Bro_swiyYm6CQ_YbyBgC9g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d2f7ed3d1940141716bfd200f5c94c6b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/heres-why-eli-lilly-lly-145004555.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/heres-why-eli-lilly-lly-145004555.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-14T16:35:00+00:00",
    "headline": "Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030",
    "summary": "Plenty of growth lies ahead for these top healthcare companies.",
    "url": "https://www.fool.com/investing/2026/01/14/prediction-best-performing-healthcare-stocks-2030/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "ac4bfc15-5902-3c6b-b5c5-5b8534fb948a",
      "content": {
        "id": "ac4bfc15-5902-3c6b-b5c5-5b8534fb948a",
        "contentType": "STORY",
        "title": "Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030",
        "description": "",
        "summary": "Plenty of growth lies ahead for these top healthcare companies.",
        "pubDate": "2026-01-14T16:35:00Z",
        "displayTime": "2026-01-14T16:35:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/18518efdb4f46e17a04e6d30428a3b1a",
          "originalWidth": 1400,
          "originalHeight": 738,
          "caption": "Researchers smile in a lab setting.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dD5LUHTacSoUwhnWc8RcVA--~B/aD03Mzg7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/18518efdb4f46e17a04e6d30428a3b1a.cf.webp",
              "width": 1400,
              "height": 738,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FigC99RHF4ydJBWyEeD81Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/18518efdb4f46e17a04e6d30428a3b1a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/01/14/prediction-best-performing-healthcare-stocks-2030/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/prediction-could-best-performing-healthcare-163500168.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-14T11:51:00+00:00",
    "headline": "Lilly, chasing Novo, expects second-quarter FDA decision on obesity pill",
    "summary": "Speaking at the J.P. Morgan conference, CEO David Ricks said he anticipates a “rapid review” for orforglipron that's currently speeding along “at pace.”",
    "url": "https://www.biopharmadive.com/news/lilly-obesity-pill-orforglipron-fda-decision-dtc-sales/809598/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "9159c265-4288-3059-acc3-04d9c9066d79",
      "content": {
        "id": "9159c265-4288-3059-acc3-04d9c9066d79",
        "contentType": "STORY",
        "title": "Lilly, chasing Novo, expects second-quarter FDA decision on obesity pill",
        "description": "",
        "summary": "Speaking at the J.P. Morgan conference, CEO David Ricks said he anticipates a “rapid review” for orforglipron that's currently speeding along “at pace.”",
        "pubDate": "2026-01-14T11:51:00Z",
        "displayTime": "2026-01-14T11:51:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/8ff02a124e40e32c10243f75d8c8a2e1",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "David Ricks, CEO of Eli Lilly, speaks alongside U.S. President Donald Trump, administration officials and fellow pharmaceutical executives on November 06, 2025 in Washington, DC.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1u9Re32Z.69y9d3.q5kNYQ--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/8ff02a124e40e32c10243f75d8c8a2e1.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8RvWVyCDOXOFlLS56Rdufw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/8ff02a124e40e32c10243f75d8c8a2e1.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/lilly-obesity-pill-orforglipron-fda-decision-dtc-sales/809598/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lilly-chasing-novo-expects-second-115100527.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]